News
-
16 July 2018
Immunocore Announces Management Change -
4 June 2018
Immunocore Presents New IMCgp100-102 Data that Show Durable Response and Robust Overall Survival Rate in Patients with Metastatic Uveal Melanoma -
22 May 2018
Immunocore to Present New Data from IMCgp100-102 Trial in Metastatic Uveal Melanoma at 2018 ASCO Annual Meeting -
21 May 2018
Immunocore wins Large Business of the Year at the 2018 Vale4Business Awards -
8 February 2018
Immunocore Announces Leadership Change -
4 January 2018
Immunocore Strengthens its Board with Appointments of Laura Wade-Gery and Kristine Peterson as Non-Executive Directors -
11 December 2017
Immunocore’s IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma -
13 November 2017
Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate -
31 October 2017
Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting -
4 October 2017
Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer